Skip to content
Peptigraph home
Shop Peptides50% off*

Does retatrutide cause constipation?

Constipation is one of the four gastrointestinal events named in the phase 2 type 2 diabetes trial, which reported gastrointestinal events in 35% of retatrutide participants versus 13% on placebo.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Constipation is one of the four gastrointestinal events named in the phase 2 type 2 diabetes trial, which reported gastrointestinal events in 35% of retatrutide participants versus 13% on placebo.[1]

In that trial's registry results, constipation affected 1 of 45 placebo participants and 5 of 46 in the top-dose step-up arm.[2]

In the diabetes phase 2 results, the arm reaching 12 mg after a 2 mg start appears as EG007.[2]

What the reviews add

A review of the phase 2 trials lists constipation among the mild-to-moderate gastrointestinal events seen mainly at the highest doses.[3]

A class-wide review calls constipation an established effect of this drug family, typically appearing at initiation and dose escalation. It is not specific to retatrutide.[4]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Side effectsWhat labels and studies report, and what is unknown.Retatrutide overview

Sources

  1. 1Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  2. 2A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  3. 3Retatrutide in type 2 diabetes mellitus and obesity: an overview.Expert review of clinical pharmacology · 2026PMID 41785010Accessed 2 Oct 2026
  4. 4Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026PMID 42808923Accessed 2 Oct 2026

Found an error? Report a correction.